Compare Eli Lilly And Co (LLY) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Oxford Lane Capital Corp — how do they compare? Eli Lilly And Co trades at $1,220.99 (market cap $1.08T), while Oxford Lane Capital Corp trades at $9.52 (market cap $909.61M). The key difference: Eli Lilly And Co is far larger — about 1187.3× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays the higher dividend (25.76%). Which is the better fit depends on your goals.
| LLY | OXLC | |
|---|---|---|
Market Cap | $1.08T | $909.61M |
Sector | Health | Financials |
52-Week High | $1.24K | $18.75 |
52-Week Low | $639.43 | $8.15 |
Enterprise Value | $1.13T | — |
Dividend Yield | 0.57% | 25.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.
Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.
OXLC trades at $9.52, up 2.7% today, with a bullish technical signal from moving averages but mixed oscillators. The stock shows a low P/B of 0.88 and a high P/S of 92.8, with recent earnings misses in Q1 and Q2 2026. Dividend payments of $0.20 per share continue monthly, supported by positive net cash flow of $252.37M in 2025. Revenue declined sharply to -$580M in 2026 from $57M in 2025, raising sustainability concerns.
Outlook is cautious due to volatile earnings and high yield risks; analyst consensus is split with 50% buy ratings. Key risks include negative ROE/ROA and potential NAV decay. Opportunities exist if dividend stability persists amid market discounts, but investor vigilance on financial health is critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
